Intellia Can't Escape Patent Suit Over $100M Regeneron Deal
Biotechnology company Intellia Therapeutics cannot ditch BlueAllele's claims that it infringed three patents related to gene editing to reap over $100 million under a deal with Regeneron Pharmaceuticals, a Pennsylvania federal...To view the full article, register now.
Already a subscriber? Click here to view full article